2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-128463
    N-tert-Butyl-α-phenylnitrone 3376-24-7 99.94%
    N-tert-Butyl-α-phenylnitrone is a nitrone-based free radical scavenger that forms nitroxide spin adducts. N-tert-Butyl-α-phenylnitrone inhibits COX2 catalytic activity. N-tert-Butyl-α-phenylnitrone has potent ROS scavenging, anti-inflammatory, neuroprotective, anti-aging and anti-diabetic activities, and can penetrate the blood-brain barrier.
    N-tert-Butyl-α-phenylnitrone
  • HY-133527
    OG 488, SE 198139-51-4
    OG 488, SE (Oregon green 488 succinimidyl ester), a fluorescent pH indicator, has many applications in biochemistry and neurosciences.
    OG 488, SE
  • HY-133910
    Lu AE98134 849000-18-6 98.02%
    Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Nav1.1 channels positive modulator. Lu AE98134 also increases the activity of Nav1.2 and Nav1.5 channels but not of Nav1.4, Nav1.6 and Nav1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Nav1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al.
    Lu AE98134
  • HY-139254
    Indirubin-3′-oxime 667463-82-3 99.10%
    Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.
    Indirubin-3′-oxime
  • HY-141711
    VU6028418 2649803-05-2 99.52%
    VU6028418 is a potent, highly selective and orally bioavailable M4 mAChR antagonist with an IC50 of 4.1 nM against hM4.
    VU6028418
  • HY-145848
    ERRγ agonist-1 98.70%
    ERRγ agonist-1 is a potent ERRγ agonist. ERRγ agonist-1 increases transcriptional activities of ERRγ. ERRγ agonist-1 has the potential for the research of neuropsychological disorders.
    ERRγ agonist-1
  • HY-150640
    Rho-Kinase-IN-2 2573071-18-6 99.29%
    Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research.
    Rho-Kinase-IN-2
  • HY-15430A
    Encenicline hydrochloride 550999-74-1 98.01%
    Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).
    Encenicline hydrochloride
  • HY-18940A
    Cilobradine hydrochloride 186097-54-1 ≥99.0%
    Cilobradine hydrochloride is a HCN channel blocker. Cilobradine hydrochloride induces cardiac pacemaker currents and produces antidepressant effects.
    Cilobradine hydrochloride
  • HY-59201A
    A-582941 dihydrochloride 848591-90-2 99.78%
    A-582941 dihydrochloride is a potent, selective and brain-penetrant partial agonist of α7 nAChR, with Kis of 10.8 and 16.7 nM in rat brain membranes and human frontal cortex, respectively. A-582941 dihydrochloride also binds to human 5-HT3 receptor with a Ki of 150 nM. A-582941 has the potential for cognitive deficits associated with various neurodegenerative and psychiatric disorders research.
    A-582941 dihydrochloride
  • HY-70053A
    Fesoterodine L-mandelate 1206695-46-6 99.00%
    Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB).
    Fesoterodine L-mandelate
  • HY-A0118A
    Naloxegol oxalate 1354744-91-4 99.91%
    Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation.
    Naloxegol oxalate
  • HY-B0551A
    Doxapram hydrochloride hydrate 7081-53-0 99.28%
    Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50 of 410 nM, 37 μM, 9 μM, respectively.
    Doxapram hydrochloride hydrate
  • HY-B1613A
    Clebopride malate 57645-91-7 99.72%
    Clebopride malate is a dopamine antagonist used in the study of functional gastrointestinal disorders.
    Clebopride malate
  • HY-E70074
    Monoamine oxidase, plasma 9001-66-5
    Monoamine oxidase (EC 1.4.3.4) is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions.
    Monoamine oxidase, plasma
  • HY-P0186A
    Endomorphin 2 TFA 1276124-00-5 99.43%
    Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioid receptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM.
    Endomorphin 2 TFA
  • HY-P0201A
    Substance P TFA 148470-19-3
    Substance P TFA (Neurokinin P TFA) is a neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).
    Substance P TFA
  • HY-P0236A
    Neurokinin A(4-10) TFA 98.84%
    Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist.
    Neurokinin A(4-10) TFA
  • HY-P1107A
    Antisauvagine-30 TFA 98.10%
    Antisauvagine-30 TFA (aSvg-30 TFA) is a potent, highly selective and competitive CRF2 receptor peptidic antagonist. Antisauvagine-30 TFA exhibits a Kd of 1.4 nM and 150 nM for mCRFR2β and CRFR1, respectively.
    Antisauvagine-30 TFA
  • HY-P1260A
    FSLLRY-NH2 TFA 99.74%
    FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor.
    FSLLRY-NH2 TFA
Cat. No. Product Name / Synonyms Application Reactivity